Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/125699
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Troya, Jesús | - |
dc.contributor.author | Ryan, Pablo | - |
dc.contributor.author | Ribera, Esteban | - |
dc.contributor.author | Podzamczer Palter, Daniel | - |
dc.contributor.author | Hontanon, Victor | - |
dc.contributor.author | Terrón, Jose Alberto | - |
dc.contributor.author | Boix, Vicente | - |
dc.contributor.author | Moreno Guillén, Santiago | - |
dc.contributor.author | Barrufet, Pilar M. | - |
dc.contributor.author | Castaño, Manuel A. | - |
dc.contributor.author | Carrero, Ana | - |
dc.contributor.author | Galindo, María José | - |
dc.contributor.author | Suárez Lozano, Ignacio | - |
dc.contributor.author | Knobel Freud, Hernando Javier | - |
dc.contributor.author | Raffo, Miguel | - |
dc.contributor.author | Solís, Javier | - |
dc.contributor.author | Yllescas, María | - |
dc.contributor.author | Esteban, Herminia | - |
dc.contributor.author | González Garcia, Juan | - |
dc.contributor.author | Berenguer, Juan | - |
dc.contributor.author | Imaz, Arkaitz | - |
dc.contributor.author | GESIDA-8314 Study Group | - |
dc.date.accessioned | 2018-10-29T14:20:12Z | - |
dc.date.available | 2018-10-29T14:20:12Z | - |
dc.date.issued | 2016-10-11 | - |
dc.identifier.uri | http://hdl.handle.net/2445/125699 | - |
dc.description.abstract | Objectives: Based on data from clinical practice, we evaluated the effectiveness and safety of switching to abacavir/lamivudine plus rilpivirine (ABC/3TC+RPV) treatment in virologically suppressed HIV-1-infected patients. Methods: We performed a multicenter, non-controlled, retrospective study of HIV-1-infected patients who switched treatment to ABC/3TC+RPV. Patients had an HIV-RNA <50 copies/mL for at least 24 weeks prior to changing treatments. The primary objective was HIV-1 RNA <50 copies/mL at week 48. Effectiveness was analyzed by intention-to-treat (ITT), missing = failure and on-treatment (OT) analyses. The secondary objectives analyzed were adverse effects changes in renal, hepatic or lipid profiles, changes in CD4+ cell count and treatment discontinuations. Results: Of the 205 patients included, 75.6% were men and the median age was 49. At baseline, before switching to ABC/3TC+RPV, median time since HIV diagnosis was 13.1 years, median time with undetectable HIV-1 RNA was 6.2 years and median time of previous antiretroviral regimen was 3.1 years (48.3% patients were taking efavirenz and ABC/3TC was the most frequent backbone coformulation in 69.7% of patients). The main reasons for switching were drug toxicity/poor tolerability (60.5%) and simplification (20%). At week 48, the primary objective was achieved by 187 out of 205 (91.2%) patients by ITT analysis, and 187 out of 192 (97.4%) patients by OT analysis. The CD4+ lymphocyte count and CD4+ percentage increased significantly from baseline to week 48 by a median of 48 cells/mu L (-50 to 189) and 1.2% (-1.3% to 4.1%), respectively, P<0.001. Thirty-eight adverse events (AE) were detected in 32 patients. Of these, 25 had no clear association with treatment. Three patients interrupted therapy due to AE. We observed a decrease in all lipid parameters, P<0.001, and a slight improvement in the glomerular filtration rate, P<0.01. Therapy was considered to have failed in 18 patients owing to virological failure (5 [2.4%]), toxicity/poor tolerability (4 [2%]), clinical decision (3 [1.5%]), loss to follow-up (3 [1.5%]), death (1 [0.5%]), and no clinical data (2 [1%]). Conclusions: The results of this study confirms that ABC/3TC+RPV is an effective, safe, and cost-effective option for the treatment of patients with virologically stable HIV-1 infection. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0164455 | - |
dc.relation.ispartof | PLoS One, 2016, vol. 11, num. 10, p. e0164455 | - |
dc.relation.uri | https://doi.org/10.1371/journal.pone.0164455 | - |
dc.rights | cc by (c) Troya et al., 2016 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | VIH (Virus) | - |
dc.subject.classification | Limfòcits | - |
dc.subject.classification | Antiretrovirals | - |
dc.subject.other | HIV (Viruses) | - |
dc.subject.other | Lymphocytes | - |
dc.subject.other | Antiretroviral agents | - |
dc.title | Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2018-07-24T12:16:12Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 27727331 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
TroyaJ.pdf | 1.7 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License